Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
USD 55.54
(0.0%)
USD 55.54
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.08 Billion EUR | 12.36% |
| 2022 | 1.85 Billion EUR | 17.29% |
| 2021 | 1.58 Billion EUR | 9.06% |
| 2020 | 1.44 Billion EUR | -2.23% |
| 2019 | 1.48 Billion EUR | 9.59% |
| 2018 | 1.35 Billion EUR | 4.98% |
| 2017 | 1.28 Billion EUR | 11.63% |
| 2016 | 1.15 Billion EUR | 10.14% |
| 2015 | 1.04 Billion EUR | 6.11% |
| 2014 | 987.35 Million EUR | 4.86% |
| 2013 | 941.63 Million EUR | 13.68% |
| 2012 | 828.31 Million EUR | 8.7% |
| 2011 | 762.03 Million EUR | 4.66% |
| 2010 | 728.13 Million EUR | -2.59% |
| 2009 | 747.52 Million EUR | 8.39% |
| 2008 | 689.63 Million EUR | 9.74% |
| 2007 | 628.43 Million EUR | 9.07% |
| 2006 | 576.18 Million EUR | 0.02% |
| 2005 | 576.08 Million EUR | 17.97% |
| 2004 | 488.3 Million EUR | 0.16% |
| 2003 | 487.53 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 607.82 Million EUR | 15.52% |
| 2024 Q2 | 577.84 Million EUR | -4.93% |
| 2023 Q4 | 526.15 Million EUR | 2.78% |
| 2023 Q2 | 492.9 Million EUR | -10.6% |
| 2023 Q1 | 551.36 Million EUR | 15.89% |
| 2023 Q3 | 511.9 Million EUR | 3.85% |
| 2023 FY | 2.08 Billion EUR | 12.36% |
| 2022 Q3 | 485.05 Million EUR | 2.52% |
| 2022 FY | 1.85 Billion EUR | 17.29% |
| 2022 Q1 | 419.38 Million EUR | -1.06% |
| 2022 Q2 | 473.1 Million EUR | 12.81% |
| 2022 Q4 | 475.76 Million EUR | -1.91% |
| 2021 Q1 | 384.83 Million EUR | 8.39% |
| 2021 Q4 | 423.88 Million EUR | 10.0% |
| 2021 Q3 | 385.35 Million EUR | -0.17% |
| 2021 FY | 1.58 Billion EUR | 9.06% |
| 2021 Q2 | 385.99 Million EUR | 0.3% |
| 2020 Q4 | 355.04 Million EUR | 6.42% |
| 2020 FY | 1.44 Billion EUR | -2.23% |
| 2020 Q1 | 429.23 Million EUR | 12.53% |
| 2020 Q2 | 330.95 Million EUR | -22.9% |
| 2020 Q3 | 333.62 Million EUR | 0.81% |
| 2019 Q3 | 357.16 Million EUR | -0.86% |
| 2019 FY | 1.48 Billion EUR | 9.59% |
| 2019 Q4 | 381.43 Million EUR | 6.79% |
| 2019 Q1 | 382.99 Million EUR | 13.0% |
| 2019 Q2 | 360.26 Million EUR | -5.93% |
| 2018 FY | 1.35 Billion EUR | 4.98% |
| 2018 Q4 | 338.92 Million EUR | 6.83% |
| 2018 Q3 | 317.25 Million EUR | -3.73% |
| 2018 Q2 | 329.55 Million EUR | -10.08% |
| 2018 Q1 | 366.5 Million EUR | 13.01% |
| 2017 Q1 | 341.94 Million EUR | 17.27% |
| 2017 Q2 | 308.92 Million EUR | -9.65% |
| 2017 Q3 | 312.95 Million EUR | 1.3% |
| 2017 FY | 1.28 Billion EUR | 11.63% |
| 2017 Q4 | 324.29 Million EUR | 3.62% |
| 2016 Q4 | 291.57 Million EUR | 6.22% |
| 2016 Q1 | 302.24 Million EUR | 14.82% |
| 2016 Q2 | 285.61 Million EUR | -5.5% |
| 2016 Q3 | 274.5 Million EUR | -3.89% |
| 2016 FY | 1.15 Billion EUR | 10.14% |
| 2015 Q4 | 263.24 Million EUR | 7.28% |
| 2015 Q1 | 275.74 Million EUR | 12.43% |
| 2015 Q2 | 263.31 Million EUR | -4.51% |
| 2015 Q3 | 245.37 Million EUR | -6.81% |
| 2015 FY | 1.04 Billion EUR | 6.11% |
| 2014 FY | 987.35 Million EUR | 4.86% |
| 2014 Q2 | 247.25 Million EUR | -5.03% |
| 2014 Q4 | 245.26 Million EUR | 4.61% |
| 2014 Q3 | 234.46 Million EUR | -5.17% |
| 2014 Q1 | 260.36 Million EUR | 8.66% |
| 2013 Q4 | 239.62 Million EUR | 6.84% |
| 2013 Q2 | 233.15 Million EUR | -4.67% |
| 2013 Q1 | 244.57 Million EUR | 17.57% |
| 2013 FY | 941.63 Million EUR | 13.68% |
| 2013 Q3 | 224.27 Million EUR | -3.81% |
| 2012 Q1 | 219.55 Million EUR | 21.03% |
| 2012 Q2 | 200.38 Million EUR | -8.73% |
| 2012 Q3 | 200.35 Million EUR | -0.02% |
| 2012 Q4 | 208.02 Million EUR | 3.83% |
| 2012 FY | 828.31 Million EUR | 8.7% |
| 2011 Q4 | 181.4 Million EUR | 1.0% |
| 2011 FY | 762.03 Million EUR | 4.66% |
| 2011 Q1 | 197.84 Million EUR | 10.22% |
| 2011 Q2 | 203.17 Million EUR | 2.7% |
| 2011 Q3 | 179.61 Million EUR | -11.6% |
| 2010 Q4 | 179.5 Million EUR | 4.14% |
| 2010 Q2 | 190.4 Million EUR | 2.45% |
| 2010 FY | 728.13 Million EUR | -2.59% |
| 2010 Q3 | 172.36 Million EUR | -9.47% |
| 2010 Q1 | 185.85 Million EUR | -2.86% |
| 2009 FY | 747.52 Million EUR | 8.39% |
| 2009 Q1 | 183.68 Million EUR | 0.0% |
| 2009 Q2 | 195.61 Million EUR | 6.49% |
| 2009 Q4 | 191.33 Million EUR | 8.17% |
| 2009 Q3 | 176.88 Million EUR | -9.57% |
| 2008 FY | 689.63 Million EUR | 9.74% |
| 2007 FY | 628.43 Million EUR | 9.07% |
| 2006 FY | 576.18 Million EUR | 0.02% |
| 2005 FY | 576.08 Million EUR | 17.97% |
| 2004 FY | 488.3 Million EUR | 0.16% |
| 2003 FY | 487.53 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AstraZeneca PLC | 46.91 Billion USD | 95.561% |
| Bristol-Myers Squibb Company PFD CONV 2 | 45 Billion USD | 95.373% |
| CSPC Pharmaceutical Group Limited | 31.45 Billion USD | 93.379% |
| Clarus Therapeutics Holdings, Inc. | 13.95 Million USD | -14819.617% |
| Novartis AG | 46.66 Billion USD | 95.537% |
| PT Kalbe Farma Tbk. | 1.97 Billion USD | -5.211% |